Skip to main content

Table 2 Changes in LogMAR BCVA in the three groups of patients

From: The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage

Variables Group A Group B Group C F P- value
LogMAR BCVA
 Baseline 2.006 ± 0.427 1.988 ± 0.463 2.05 ± 0.412 0.087 0.917
 Month 3 0.706 ± 0.277 0.488 ± 0.189 0.463 ± 0.159 6.272 0.004